IS-free Treg HaploHCT

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Dana-Farber Cancer Institute
Updated on 8 July 2022
myelodysplastic syndromes
ejection fraction
cell transplantation
gilbert's syndrome
blast cells


This research study is evaluating the safety and efficacy of the IS-free Treg-cell graft-engineered haplo transplant method in people with relapsed/refractory acute myeloid leukemia (AML) and/or myelodysplastic syndromes (MDS) receiving a haploidentical donor allogeneic hematopoietic stem cell transplant (HSCT).

The names of the study interventions involved in this study are:

  • Radiation-Total Myeloid and Lymphoid Irradiation (TMLI
  • Chemotherapy (Fludarabine, Thiotepa, Cyclophosphamide plus Mesna)
  • Infusion of haplo Treg-enriched donor cells (experimental therapy)
  • Infusion of unmodified haplo donor T cells (includes cancer-fighting T effector cells)
  • Infusion of haplo donor CD34+ Peripheral Blood Stem Cells


This study is assessing whether the IS-free Treg-cell graft-engineered haplo HSCT) approach will reduce risk of relapse while preventing usual toxicities related to stem cell transplants (e.g., graft-versus-host-disease (GVHD)). GVHD is a complication of transplantation where the T cells (a type of white blood cell that helps protect the body from relapse by killing cancer cells) in the donor graft attack and damage some of the host tissues. Patients who receive an allogeneic (using another person as the donor) hematopoietic stem cell transplant (HSCT) may develop graft-versus-host disease (GVHD) toxicity and are also at risk of disease relapse.

The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits.

Participants will receive the study intervention Treg-enriched donor cells and will then be followed for 1 year after transplantation.

It is expected that about 10 people will take part in this research study.

Dana-Farber Cancer Institute research funds along with charitable donations are supporting this research study. Regeneron Pharmaceuticals, Inc. (a pharmaceutical company) is also supporting this research study by providing funding and support for correlative laboratory tests.

Condition Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute, Myeloid Leukemia in Relapse (Disorder), Myelodysplastic Syndromes
Treatment cyclophosphamide, Fludarabine, MESNA, Radiation, thiotepa, Treg-enriched donor cell, Unmodified donor T Cell, CD34+ Haplo Peripheral Blood Stem Cell
Clinical Study IdentifierNCT04678401
SponsorDana-Farber Cancer Institute
Last Modified on8 July 2022


Yes No Not Sure

Inclusion Criteria

Histologically-confirmed disease in the prior 4 weeks, despite at least 1 prior line of therapy (e.g., 3+7 chemotherapy, HMA therapy): Rel/ref AML (de novo or secondary) with ≥5% blasts in BM (or extramedullary sites); MDS EB-2 (BM >10% blasts, PB 5-19% blasts)
Available haploidentical HLA-matched (-A, -B, -C, -DRB1) related donor aged 18-65 years
Age ≥18 to 65 years. Older patients are not candidates for myeloablative HCT. Because no dosing or adverse event data are currently available on the use of IS-free haploHCT in participants <18 years of age, children are excluded from this study, but will be eligible for future pediatric trials
ECOG performance status ≤2 (Karnofsky ≥60, see Appendix A)
Adequate organ and marrow function as defined below
Pulmonary Function: FEV1, FVC and DLCO ≥ 60% of predicted (corrected for hemoglobin)
Cardiac Ejection Fraction ≥ 45%, and no evidence of pulmonary hypertension
Hepatic: Total bilirubin within normal institutional limits (exception permitted in Gilbert's Syndrome after discussion with study PI, on a case by case basis); and AST (SGOT)/ALT (SGPT) <2x institutional upper limit of normal
Renal: Serum Creatinine within normal institutional limits or creatinine clearance > 50 mL/min/1.73 m2 (see Appendix B) for participants with creatinine levels above institutional normal
The effects of IS-free haploHCT on the developing human fetus are unknown. For this
reason and because radiation and chemotherapeutic agents are known to be
Ability to understand and the willingness to sign a written informed consent document
teratogenic, women of child-bearing potential and men must agree to use
adequate contraception (hormonal or barrier method of birth control
abstinence) prior to study entry and for the duration of study participation
Should a woman become pregnant or suspect she is pregnant while she or her
partner is participating in this study, she should inform her treating
physician immediately. Men treated or enrolled on this protocol must also
agree to use adequate contraception prior to the study, for the duration of
study participation, and a minimum of 4 months after completion of study

Exclusion Criteria

Participants who have had cytotoxic chemotherapy or radiotherapy within 2 weeks (4 weeks for nitrosoureas or mitomycin C) prior to entering the study. Use of hydroxyurea, HMA, e.g., azacytidine, decitabine) and/or FDA-approved novel targeted agents (e.g., venetoclax, FLT-3 inhibitors, IDH 1/2 inhibitors) are permitted up to day prior to start of HCT conditioning
Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual non-hematologic toxicities > Grade 1) with exception of alopecia, unless cleared by study PI
Participants who received Mylotarg or other therapies associated with increased risk of hepatic veno-occlusive disease (VOD) or have known prior or active VOD. All novel therapies will be reviewed with PI
Participants who are receiving any other investigational agents within 21 days (or 5 halflives) prior to study entry, whichever is longer, unless cleared by the study PI
Participants with extramedullary disease at immune privileged sites (e.g., CNS, testes, eye) are excluded, as these sites are less susceptible to the curative graft vs. leukemia effect of HCT
Myocardial infarction within 2 years prior to enrollment
Venous thromboembolic event (VTE) of DVT/ PE within 1 year prior to enrollment. Patients with line-associated DVT within the past year may be enrolled if they have completed anticoagulation therapy
Stroke or transient ischemic attack (TIA) within 1 year prior to enrollment
History of bleeding peptic ulcer disease, erosive gastritis, intestinal perforation or clinically significant gastrointestinal (GI) hemorrhage or hemoptysis within the prior 6 months
Patients with a history of thrombotic microangiopathy (TMA) or hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP)
History of life-threatening reactions to iron infusions or murine antibody-containing products
Known donor-specific antibodies (DSA) in the recipient of clinical significance (e.g., requiring DSA depletion with plasmapheresis, rituximab) are excluded
Inability to withhold agents that may interact with hepatic cytochrome P450 enzymes involved in cyclophosphamide and/or thiotepa metabolism (see Section 5.5) during day - 10 through day -5. It is acceptable use alternative non-interacting medications during this period, and then restart prior medications
Participants with uncontrolled bacterial, viral or fungal infections (i.e., currently taking medications with progression of clinical symptoms or signs)
Recipients of prior allogeneic or autologous hematopoietic cell transplantation, or solid organ transplantation
Prior radiation exposure or other medical condition (e.g., Fanconi syndrome) that precludes use of myeloablative radiation (TMLI)
HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with the multiple agents used routinely in myeloablative allogeneic stem cell transplantation. In addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy
Appropriate studies will be undertaken in participants receiving combination antiretroviral
therapy when indicated
Participants seropositive for hepatitis B or C infection are ineligible as they are at
high risk of lethal treatment-related hepatotoxicity after myeloablative HCT
Participants with psychiatric illness/social situations that would limit compliance
with study requirements
Pregnant women are excluded from this study because radiation and conditioning
chemotherapy has the potential for teratogenic or abortifacient effects. A negative
pregnancy test is required for females of childbearing potential. Because there is an
unknown but potential risk for adverse events in nursing infants secondary to
treatment of the mother with IS-free haploHCT breastfeeding should be discontinued if
the mother is treated with IS-free haploHCT
Participants with a history of another non-hematologic malignancy are ineligible
except for the following circumstances: Individuals with a history of other
malignancies are eligible if they have been disease-free for at least 5 years and are
deemed by the investigator to be at low risk for recurrence of that malignancy
Individuals with the following cancers are eligible if diagnosed and treated within
the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma
of the skin
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note